2024
HEALTH CARE UTILIZATION AND COSTS FOR HOSPITALIZED DEMENTIA PATIENTS IN CHINA
Lin Z, Ba F, Allore H, Chen X. HEALTH CARE UTILIZATION AND COSTS FOR HOSPITALIZED DEMENTIA PATIENTS IN CHINA. Innovation In Aging 2024, 8: 954-955. PMCID: PMC11691564, DOI: 10.1093/geroni/igae098.3077.Peer-Reviewed Original ResearchLength of stayInsurance coverageCare utilizationDementia patientsPrimary diagnosis of dementiaInsurance typeTertiary hospitalTertiary hospital admissionChronic disease managementChinese older adultsHealth care utilizationInpatient care utilizationDiagnosis of dementiaEmergency roomOlder patientsLower-level hospitalsIncreased adjusted oddsLow insurance coverageDeterminants of length of stayMultivariate logistic regressionDementia careHealthcare utilizationHospital levelOlder adultsAdjusted oddsIN-HOSPITAL MORTALITY AMONG DEMENTIA PATIENTS IN CHINA: EVIDENCE FROM HOSPITAL ADMINISTRATIVE DATA
Lin Z, Ba F, Allore H, Chen X. IN-HOSPITAL MORTALITY AMONG DEMENTIA PATIENTS IN CHINA: EVIDENCE FROM HOSPITAL ADMINISTRATIVE DATA. Innovation In Aging 2024, 8: 955-956. PMCID: PMC11691659, DOI: 10.1093/geroni/igae098.3080.Peer-Reviewed Original ResearchDementia careIn-Hospital MortalityDementia patientsPrimary diagnosis of dementiaQuality dementia careAssociation of in-hospital mortalityOdds of in-hospital mortalityChinese older adultsDiagnosis of dementiaHospital-level factorsLower-level hospitalsInpatient medical recordsReduced in-hospital mortalityHigher-level counterpartsMultivariate logistic regressionHospital levelHospital characteristicsHospital transferOlder adultsWork statusAdmission typeInsurance typeAge bandsPatient levelDementiaHEALTH CARE UTILIZATION AND COSTS FOR HOSPITALIZED DEMENTIA PATIENTS IN CHINA
Lin Z, Ba F, Allore H, Chen X. HEALTH CARE UTILIZATION AND COSTS FOR HOSPITALIZED DEMENTIA PATIENTS IN CHINA. Innovation In Aging 2024, 8: 1124-1124. PMCID: PMC11693179, DOI: 10.1093/geroni/igae098.3607.Peer-Reviewed Original ResearchLength of stayInsurance coverageCare utilizationDementia patientsPrimary diagnosis of dementiaInsurance typeTertiary hospitalTertiary hospital admissionChronic disease managementChinese older adultsHealth care utilizationInpatient care utilizationDiagnosis of dementiaEmergency roomOlder patientsLower-level hospitalsIncreased adjusted oddsLow insurance coverageDeterminants of length of stayMultivariate logistic regressionDementia careHealthcare utilizationHospital levelOlder adultsAdjusted oddsSex‐specific topological structure associated with dementia via latent space estimation
Wang S, Wang Y, Xu F, Tian X, Fredericks C, Shen L, Zhao Y, Initiative F. Sex‐specific topological structure associated with dementia via latent space estimation. Alzheimer's & Dementia 2024, 20: 8387-8401. PMID: 39530632, PMCID: PMC11667551, DOI: 10.1002/alz.14266.Peer-Reviewed Original Research
2023
Aging gene signature of memory CD8+ T cells is associated with neurocognitive functioning in Alzheimer’s disease
Young J, Park H, Kim M, Par-Young J, Bartlett H, Kim H, Unlu S, Osmani L, Shin M, Bucala R, van Dyck C, Allore H, Mecca A, You S, Kang I. Aging gene signature of memory CD8+ T cells is associated with neurocognitive functioning in Alzheimer’s disease. Immunity & Ageing 2023, 20: 71. PMID: 38042785, PMCID: PMC10693128, DOI: 10.1186/s12979-023-00396-y.Peer-Reviewed Original ResearchPeripheral bloodT cellsAlzheimer's diseaseEM CD8Memory CD8Gene signatureAge-related immune changesIL-7 receptor alphaEffector memory CD8Strong risk factorT cell expansionAD genesAge-associated expansionImmune changesRisk factorsCD8Dementia patientsIL-7RNeuropsychological testingReceptor alphaNeurocognitive functionRT-qPCR resultsDisease severityPatientsNormal personsHistone deacetylase inhibitors mitigate antipsychotic risperidone-induced motor side effects in aged mice and in a mouse model of Alzheimer’s disease
Rodriguez G, Fisher D, McClarty B, Montalvo-Ortiz J, Cui Q, Chan C, Dong H. Histone deacetylase inhibitors mitigate antipsychotic risperidone-induced motor side effects in aged mice and in a mouse model of Alzheimer’s disease. Frontiers In Psychiatry 2023, 13: 1020831. PMID: 36684015, PMCID: PMC9852991, DOI: 10.3389/fpsyt.2022.1020831.Peer-Reviewed Original ResearchMotor side effectsSevere neuropsychiatric symptomsAged miceSide effectsHDAC inhibitorsNeuropsychiatric symptomsDementia patientsHistone deacetylase inhibitor valproic acidAtypical antipsychotic risperidoneTypical antipsychotic haloperidolAntipsychotic drug targetsGreater side effectsInhibitor valproic acidHistone deacetylase inhibitorsAge-related sensitivityEpigenetic alterationsAtypical antipsychoticsD2R expressionAntipsychotic haloperidolLabel useAntipsychotic risperidoneAntipsychotic drugsMouse modelValproic acidClinical practice
2022
Geographic Variation in Inpatient Care Utilization, Outcomes and Costs for Dementia Patients Aged 65 Years or Older — China, 2017–2019
Lin Z, Ba F, Allore H, Liu G, Chen X. Geographic Variation in Inpatient Care Utilization, Outcomes and Costs for Dementia Patients Aged 65 Years or Older — China, 2017–2019. China CDC Weekly 2022, 4: 997-1001. PMID: 36483008, PMCID: PMC9709301, DOI: 10.46234/ccdcw2022.202.Peer-Reviewed Original ResearchPatients Aged 65 YearsDementia careInpatient care utilizationPublic health issuePublic health practicePublic health policyDementia managementCare utilizationHealthcare utilizationDisease burdenDementia patientsHealth servicesHealth practicesHealth policyHealth issuesGeographic disparitiesDementiaHealthcare systemHealthcare provisionPatientsPublic healthCareImproved accessOutcomesBurden
2019
30‐Day Emergency Department Revisit Rates among Older Adults with Documented Dementia
Kent T, Lesser A, Israni J, Hwang U, Carpenter C, Ko KJ. 30‐Day Emergency Department Revisit Rates among Older Adults with Documented Dementia. Journal Of The American Geriatrics Society 2019, 67: 2254-2259. PMID: 31403717, PMCID: PMC6899685, DOI: 10.1111/jgs.16114.Peer-Reviewed Original ResearchConceptsIndex ED visitED revisitsEmergency departmentED visitsDementia diagnosisIndex encounterOdds ratioOlder adultsMedicare beneficiariesEmergency department revisit rateRevisit ratesED revisit ratesHigh ED utilizationSignificant predictorsNational emergency departmentSkilled nursing facilitiesLogistic regression modelsDementia codesED utilizationMedicaid statusOutpatient claimsRepresentative sampleContinuous feeClaims dataDementia patientsDEMENTIA: A COGNITIVE DISABILITY AND ROLE OF NON-PHARMACOLOGICAL INTERVENTION ALZHATV IN COGNITIVE REMEDIATION
Varshney S, McCall W, Tampi R, Varshney U. DEMENTIA: A COGNITIVE DISABILITY AND ROLE OF NON-PHARMACOLOGICAL INTERVENTION ALZHATV IN COGNITIVE REMEDIATION. American Journal Of Geriatric Psychiatry 2019, 27: s152-s154. DOI: 10.1016/j.jagp.2019.01.107.Peer-Reviewed Original ResearchNPI-NH scoresNPI-NHNursing home patientsNon-pharmacological interventionsReality orientationDementia patientsPsychotropic medicationsHome patientsFamily membersCognitive remediationActivities of daily livingCognitive trainingNursing home staffCognitive disabilitiesVascular dementia patientsFamily videosSpousal caregiversHome staffOverall agitationMild-to-moderate Alzheimer's diseaseNursing homesDaily livingDecrease agitationManaging agitationModerate Alzheimer's disease
2018
Alzhatv: A Nonpharmacological Intervention to Manage Behavioral and Psychological Symptoms in Nursing Home Dementia Patients
Varshney S, Varshney J, Tampi R, McCall W, Varshney U. Alzhatv: A Nonpharmacological Intervention to Manage Behavioral and Psychological Symptoms in Nursing Home Dementia Patients. Annals Of Clinical Psychiatry 2018, 30: 122-132. PMID: 29697713, DOI: 10.1177/104012371803000207.Peer-Reviewed Original ResearchConceptsPsychological symptomsNonpharmacological interventionsOverall cost of health careAntipsychotic medicationNeurocognitive disordersCost of health careAssociated with neurocognitive disordersNursing facilitiesHome patientsDementia patientsHealth carePsychiatric symptomsFamily membersNursesCaregiversDementiaAssisted livingInterventionDisordersSymptomsMedicationBenzodiazepinesAlzheimer's diseaseCase seriesPatients
2017
Psychological Suffering in Essential Tremor: A Study of Patients and Those Who Are Close to Them
Monin J, Gutierrez J, Kellner S, Morgan S, Collins K, Rohl B, Migliore F, Cosentino S, Huey E, Louis E. Psychological Suffering in Essential Tremor: A Study of Patients and Those Who Are Close to Them. Tremor And Other Hyperkinetic Movements 2017, 7: 526. DOI: 10.5334/tohm.338.Peer-Reviewed Original ResearchNumber of medicationsET patientsEssential tremorTremor severityOverall sufferingCognitive statusPatients’ psychological sufferingNon-motor featuresStudy of patientsPsychological sufferingPatients' cognitive statusOwn depressive symptomsDaily stressPatient depressionDementia patientsDepressive symptomsPatientsPatient experienceMultidisciplinary teamSupportive interventionsMedicationsSeverityRegression modelsTremorDepressionHyperinsulinemia and elevated systolic blood pressure independently predict white matter hyperintensities with associated cognitive decrement in the middle-aged offspring of dementia patients
Hawkins KA, Emadi N, Pearlson GD, Winkler AM, Taylor B, Dulipsingh L, King D, Pittman B, Blank K. Hyperinsulinemia and elevated systolic blood pressure independently predict white matter hyperintensities with associated cognitive decrement in the middle-aged offspring of dementia patients. Metabolic Brain Disease 2017, 32: 849-857. PMID: 28255864, DOI: 10.1007/s11011-017-9980-9.Peer-Reviewed Original ResearchConceptsSystolic blood pressureWMH volumeVascular riskBlood pressurePlasma insulinDementia patientsMRI white matter hyperintensity volumeCognitive declineElevated systolic blood pressureSmall dense LDL-cholesterolWhite matter hyperintensity volumeH systolic BPIndependent risk factorDense LDL cholesterolCognitive decrementsBody mass indexWhite matter damageWhite matter hyperintensitiesApoE ε4 effectMiddle-aged offspringCerebral infarctsLifestyle modificationAggressive treatmentCerebrovascular damageLDL cholesterol
2016
Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer’s disease
Zhang X, Mormino E, Sun N, Sperling R, Sabuncu M, Yeo B, Weiner M, Aisen P, Weiner M, Aisen P, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Saykin A, Morris J, Shaw L, Khachaturian Z, Sorensen G, Carrillo M, Kuller L, Raichle M, Paul S, Davies P, Fillit H, Hefti F, Holtzman D, Mesulam M, Potter W, Snyder P, Schwartz A, Green R, Montine T, Petersen R, Aisen P, Thomas R, Donohue M, Walter S, Gessert D, Sather T, Jiminez G, Balasubramanian A, Mason J, Sim I, Beckett L, Harvey D, Donohue M, Jack C, Bernstein M, Fox N, Thompson P, Schuff N, DeCArli C, Borowski D, Gunter J, Senjem M, Vemuri P, Jones D, Kantarci K, Ward C, Jagust W, Koeppe R, Foster N, Reiman E, Chen K, Mathis C, Landau S, Morris J, Cairns N, Franklin E, Taylor-Reinwald L, Shaw L, Trojanowki J, Lee V, Korecka M, Figurski M, Toga A, Crawford K, Neu S, Saykin A, Foroud T, Potkin S, Shen L, Faber K, Kim S, Nho K, Weiner M, Thal L, Khachaturian Z, Thal L, Buckholtz N, Weiner M, Snyder P, Potter W, Paul S, Albert M, Frank R, Khachaturian Z, Hsiao J, Kaye J, Quinn J, Silbert L, Lind B, Carter R, Dolen S, Schneider L, Pawluczyk S, Becerra M, Teodoro L, Spann B, Brewer J, Vanderswag H, Fleisher A, Heidebrink J, Lord J, Petersen R, Mason S, Albers C, Knopman D, Johnson K, Doody R, Villanueva-Meyer J, Pavlik V, Shibley V, Chowdhury M, Rountree S, Dang M, Stern Y, Honig L, Bell K, Ances B, Morris J, Carroll M, Creech M, Franklin E, Mintun M, Schneider S, Oliver A, Marson D, Geldmacher D, Love M, Griffith R, Clark D, Brockington J, Roberson E, Grossman H, Mitsis E, Shah R, deToledo-Morrell L, Duara R, Greig-Custo M, Barker W, Albert M, Onyike C, D’Agostino D, Kielb S, Sadowski M, Sheikh M, Ulysse A, Gaikwad M, Doraiswamy P, Petrella J, Borges-Neto S, Wong T, Coleman E, Arnold S, Karlawish J, Wolk D, Clark C, Smith C, Jicha G, Hardy P, Sinha P, Oates E, Conrad G, Lopez O, Oakley M, Simpson D, Porsteinsson A, Goldstein B, Martin K, Makino K, Ismail M, Brand C, Potkin S, Preda A, Nguyen D, Womack K, Mathews D, Quiceno M, Levey A, Lah J, Cellar J, Burns J, Swerdlow R, Brooks W, Apostolova L, Tingus K, Woo E, Silverman D, Lu P, Bartzokis G, Graff-Radford N, Parfitt F, Poki-Walker K, Farlow M, Hake A, Matthews B, Brosch J, Herring S, van Dyck C, Carson R, MacAvoy M, Varma P, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Hsiung G, Mudge B, Sossi V, Feldman H, Assaly M, Finger E, Pasternack S, Rachisky I, Trost D, Kertesz A, Bernick C, Munic D, Mesulam M, Rogalski E, Lipowski K, Weintraub S, Bonakdarpour B, Kerwin D, Wu C, Johnson N, Sadowsky C, Villena T, Turner R, Johnson K, Reynolds B, Sperling R, Johnson K, Marshall G, Yesavage J, Taylor J, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Sirrel S, Kowall N, Killiany R, Budson A, Norbash A, Johnson P, Obisesan T, Wolday S, Allard J, Lerner A, Ogrocki P, Tatsuoka C, Fatica P, Fletcher E, Maillard P, Olichney J, DeCarli C, Carmichael O, Kittur S, Borrie M, Lee T, Bartha R, Johnson S, Asthana S, Carlsson C, Potkin S, Preda A, Nguyen D, Tariot P, Burke A, Milliken A, Trncic N, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre D, Kataki M, Kelley B, Zimmerman E, Celmins D, Brown A, Pearlson G, Blank K, Anderson K, Flashman L, Seltzer M, Hynes M, Santulli R, Sink K, Gordineer L, Williamson J, Garg P, Watkins F, Ott B, Tremont G, Daiello L, Salloway S, Malloy P, Correia S, Rosen H, Miller B, Perry D, Mintzer J, Spicer K, Bachman D, Finger E, Pasternak S, Rachinsky I, Rogers J, Kertesz A, Drost D, Pomara N, Hernando R, Sarrael A, Schultz S, Smith K, Koleva H, Nam K, Shim H, Relkin N, Chiang G, Lin M, Ravdin L, Smith A, Raj B, Fargher K. Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer’s disease. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: e6535-e6544. PMID: 27702899, PMCID: PMC5081632, DOI: 10.1073/pnas.1611073113.Peer-Reviewed Original ResearchConceptsAtrophy factorAtrophy patternsCortical factorsDementia patientsAlzheimer's disease dementia patientsDistinct atrophy patternsStrong associationEntire clinical spectrumAD dementia patientsExecutive function declineExecutive functionSubcortical factorsFunction declineClinical spectrumEarly ADAlzheimer's diseaseStructural MRIDisease monitoringNormal participantsMemory declineMCI participantsDifferent cognitive domainsPatientsFactor compositionCognitive trajectories
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply